Catalyst Pharmaceuticals Inc (STU:CN2)
€ 20.71 0.15 (0.73%) Market Cap: 2.46 Bil Enterprise Value: 2.04 Bil PE Ratio: 18.19 PB Ratio: 3.87 GF Score: 88/100

Q2 2024 Catalyst Pharmaceuticals Inc Earnings Call Transcript

Aug 08, 2024 / 12:30PM GMT
Release Date Price: €15 (+1.63%)
Operator

Greetings, and welcome to the Catalyst Pharmaceuticals' second quarter 2024 financial results conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. (Operator Instructions) As a reminder, this conference is being recorded.

It is now my pleasure to introduce your host, Michael Kalb, CFO. Thank you, Michael. You may begin.

Michael W Kalb
Catalyst Pharmaceuticals Inc - Executive Vice President & Chief Financial Officer

Thank you. Good morning, everyone, and thank you for joining our conference call to discuss Catalyst's second quarter 2024 financial results and business highlights. Richard Daly, President and CEO will be leading the call today, and Jeffrey Del Carmen, our Chief Commercial Officer, and I will also present. Additionally, Dr. Steven Miller, our Chief Operating Officer and $Scientific Officer will be available for the Q&A.

Before we begin, I would like to remind you that in our remarks this morning and in the Q&A session, we

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot